Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project

Paul L. Hess; Kevin Kennedy; Michael Cowherd; Salim S. Virani; Frederick A. Masoudi; Ann Marie Navar; Robert W. Yeh; P. Michael Ho; Thomas M. Maddox

doi:10.1016/j.ahj.2017.09.004

Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project

Paul L. Hess, Kevin Kennedy, Michael Cowherd, Salim S. Virani, Frederick A. Masoudi, Ann Marie Navar, Robert W. Yeh, P. Michael Ho, Thomas M. Maddox

Research output: Contribution to journal › Letter › peer-review

5 Scopus citations

Original language	English (US)
Pages (from-to)	151-152
Number of pages	2
Journal	American heart journal
Volume	195
DOIs	https://doi.org/10.1016/j.ahj.2017.09.004
State	Published - Jan 2018
Externally published	Yes

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.ahj.2017.09.004

Cite this

Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice : An NCDR Research to Practice (R2P) project. / Hess, Paul L.; Kennedy, Kevin; Cowherd, Michael; Virani, Salim S.; Masoudi, Frederick A.; Navar, Ann Marie; Yeh, Robert W.; Ho, P. Michael; Maddox, Thomas M.

In: American heart journal, Vol. 195, 01.2018, p. 151-152.

Research output: Contribution to journal › Letter › peer-review

Hess, Paul L. ; Kennedy, Kevin ; Cowherd, Michael ; Virani, Salim S. ; Masoudi, Frederick A. ; Navar, Ann Marie ; Yeh, Robert W. ; Ho, P. Michael ; Maddox, Thomas M. / Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice : An NCDR Research to Practice (R2P) project. In: American heart journal. 2018 ; Vol. 195. pp. 151-152.

@article{17826a78f9e04794a2be14d46a89a769,

title = "Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project",

author = "Hess, {Paul L.} and Kevin Kennedy and Michael Cowherd and Virani, {Salim S.} and Masoudi, {Frederick A.} and Navar, {Ann Marie} and Yeh, {Robert W.} and Ho, {P. Michael} and Maddox, {Thomas M.}",

note = "Funding Information: This research was supported by the American College of Cardiology National Cardiovascular Data Registry . The PINNACLE Registry is an initiative of the American College of Cardiology. Bristol-Myers Squibb and Pfizer Inc are founding sponsors of the PINNACLE Registry. The PINNACLE Registry and the National Cardiovascular Data Registry had no role in the design or conduct of the study, the management or analysis performed in the study, or the interpretation of the data. Dr Masoudi is the Chief Medical Officer for the NCDR. Dr. Navar is supported by the National Heart, Lung, and Blood Institute (K01HL133416), and reports research support from Regeneron/Sanofi, and Amgen, Inc., and support as a consultant for Sanofi and Amgen, Inc. Other authors have no relevant disclosures.",

year = "2018",

month = jan,

doi = "10.1016/j.ahj.2017.09.004",

language = "English (US)",

volume = "195",

pages = "151--152",

journal = "American Heart Journal",

issn = "0002-8703",

publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice

T2 - An NCDR Research to Practice (R2P) project

AU - Hess, Paul L.

AU - Kennedy, Kevin

AU - Cowherd, Michael

AU - Virani, Salim S.

AU - Masoudi, Frederick A.

AU - Navar, Ann Marie

AU - Yeh, Robert W.

AU - Ho, P. Michael

AU - Maddox, Thomas M.

N1 - Funding Information: This research was supported by the American College of Cardiology National Cardiovascular Data Registry . The PINNACLE Registry is an initiative of the American College of Cardiology. Bristol-Myers Squibb and Pfizer Inc are founding sponsors of the PINNACLE Registry. The PINNACLE Registry and the National Cardiovascular Data Registry had no role in the design or conduct of the study, the management or analysis performed in the study, or the interpretation of the data. Dr Masoudi is the Chief Medical Officer for the NCDR. Dr. Navar is supported by the National Heart, Lung, and Blood Institute (K01HL133416), and reports research support from Regeneron/Sanofi, and Amgen, Inc., and support as a consultant for Sanofi and Amgen, Inc. Other authors have no relevant disclosures.

PY - 2018/1

Y1 - 2018/1

UR - http://www.scopus.com/inward/record.url?scp=85032885957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032885957&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2017.09.004

DO - 10.1016/j.ahj.2017.09.004

M3 - Letter

C2 - 29224643

AN - SCOPUS:85032885957

VL - 195

SP - 151

EP - 152

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

ER -